Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Aug;16(4):236-40.
doi: 10.3132/pcrj.2007.00047.

The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD)

Affiliations

The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD)

Rachel Garrod et al. Prim Care Respir J. 2007 Aug.

Abstract

Aims: To examine relationships between markers of systemic inflammation and functional status in patients with chronic obstructive pulmonary disease (COPD).

Methods: 41 COPD patients were stratified using the Medical Research Council (MRC) dyspnoea scale. Six-minute walking distance (6MWD), Quadriceps (% body weight) (QBW), St George's Hospital Respiratory Questionnaire (SGRQ), London Chest Activity of Daily Living Scale (LCADL), C-reactive protein (CRP), interleukin 6 (IL6), tumour necrosis factor alpha, and neopterin were measured. Relationships between variables and differences in inflammatory markers between MRC categories were tested.

Results: Inflammation increased with MRC grade and was significantly different across grades; CRP (p=0.002) and IL6 (p=0.04). Relationships were evident between CRP, 6MWD, LCADL and SGRQ, r=-0.47, 0.50, 0.43 (all p<0.01) respectively, and between IL6, QBW and LCADL, rho=-0.36, 0.51 (p<0.05).

Conclusions: Measures of systemic inflammation, and in particular CRP, may prove to be useful markers in the assessment of COPD severity in primary care.

PubMed Disclaimer

Conflict of interest statement

Rachel Garrod has worked as a consultant for GSK and Boehhnger/Pfizer, and gives talks for both companies. She has received funding from GSK up to $60,000

G Hagan is employed by GSK

All other authors have no conflicts of interest

Publication types

MeSH terms